Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Screening asymptomatic patients with type 2 diabetes mellitus for coronary artery disease: does it improve patient outcome?

Shirani J, Dilsizian V.

Curr Cardiol Rep. 2010 Mar;12(2):140-6. doi: 10.1007/s11886-010-0091-z. Review.

PMID:
20425169
2.

PPAR Agonists and Cardiovascular Disease in Diabetes.

Calkin AC, Thomas MC.

PPAR Res. 2008;2008:245410. doi: 10.1155/2008/245410.

3.

The role of fibrates in the prevention of cardiovascular disease--a pooled meta-analysis of long-term randomized placebo-controlled clinical trials.

Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR.

Am Heart J. 2007 Nov;154(5):943-53. Epub 2007 Sep 12. Review.

PMID:
17967602
4.

Optimizing cardiovascular outcomes in diabetes mellitus.

Sobel BE.

Am J Med. 2007 Sep;120(9 Suppl 2):S3-11. Review.

PMID:
17826044
5.

Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse.

Calkin AC, Allen TJ, Lassila M, Tikellis C, Jandeleit-Dahm KA, Thomas MC.

Atherosclerosis. 2007 Nov;195(1):17-22. Epub 2007 Jan 9.

PMID:
17214990
6.

Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema?

Mittra S, Sangle G, Tandon R, Sharma S, Roy S, Khanna V, Gupta A, Sattigeri J, Sharma L, Priyadarsiny P, Khattar SK, Bora RS, Saini KS, Bansal VS.

Br J Pharmacol. 2007 Feb;150(4):480-7. Epub 2007 Jan 8.

7.

Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?

Becker J, Delayre-Orthez C, Frossard N, Pons F.

Fundam Clin Pharmacol. 2006 Oct;20(5):429-47. Review.

PMID:
16968414
8.

Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation.

Calkin AC, Cooper ME, Jandeleit-Dahm KA, Allen TJ.

Diabetologia. 2006 Apr;49(4):766-74. Epub 2006 Feb 4.

PMID:
16463048
9.

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

Nissen SE, Wolski K, Topol EJ.

JAMA. 2005 Nov 23;294(20):2581-6. Epub 2005 Oct 20.

PMID:
16239637
10.

Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators.

Han SH, Quon MJ, Koh KK.

Hypertension. 2005 Nov;46(5):1086-92. Epub 2005 Oct 17. Review.

11.

Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects.

Calkin AC, Forbes JM, Smith CM, Lassila M, Cooper ME, Jandeleit-Dahm KA, Allen TJ.

Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1903-9. Epub 2005 Jul 14.

13.

Evidence for a potent antiinflammatory effect of rosiglitazone.

Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P.

J Clin Endocrinol Metab. 2004 Jun;89(6):2728-35.

PMID:
15181049
14.

Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.

Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S.

Circulation. 2004 May 11;109(18):2197-202. Epub 2004 May 3.

15.
16.

Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models.

Chakrabarti R, Vikramadithyan RK, Misra P, Hiriyan J, Raichur S, Damarla RK, Gershome C, Suresh J, Rajagopalan R.

Br J Pharmacol. 2003 Oct;140(3):527-37. Epub 2003 Sep 1.

17.

Homocysteine mediated expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human monocytes.

Zeng X, Dai J, Remick DG, Wang X.

Circ Res. 2003 Aug 22;93(4):311-20. Epub 2003 Jul 24.

18.

Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice.

Mardones P, Pilon A, Bouly M, Duran D, Nishimoto T, Arai H, Kozarsky KF, Altayo M, Miquel JF, Luc G, Clavey V, Staels B, Rigotti A.

J Biol Chem. 2003 Mar 7;278(10):7884-90. Epub 2003 Jan 2.

19.

The mechanisms of action of PPARs.

Berger J, Moller DE.

Annu Rev Med. 2002;53:409-35. Review.

PMID:
11818483
20.

Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall.

Chinetti G, Fruchart JC, Staels B.

Z Kardiol. 2001;90 Suppl 3:125-32. Review.

PMID:
11374025

Supplemental Content

Support Center